Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegis Capital Adjusts PT on Stemline (STML) to $55 Following Financing, Development Update
January 30, 2015 9:49 AM ESTAegis Capital lowers its price target on Stemline Therapeutics (Nasdaq: STML) from $68 to $55 and maintains a Buy rating on the stock following a recent financing round and development update.
Analyst Yi Chen commented, Stemline Therapeutics recently announced that it had licensed from... More
Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment
January 30, 2015 8:43 AM ESTStemline Therapeutics (NASDAQ: STML) announced that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.
SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that... More
